Effectiveness and duration of use of long term contraceptives

• Grant number: 12/13152-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: November 01, 2012
• End date: October 31, 2014
• Field of knowledge: Health Sciences - Medicine - Maternal and Child Health
• Principal Investigator: Luis Guillermo Bahamondes
• Grantee: Bruna Fernanda Bottura
• Host Institution: Centro de Atenção Integral à Saúde da Mulher (CAISM). Hospital da Mulher Professor Doutor José Aristodemo Pinotti. Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

The objectives of the present study will be to know the failure rates, the continuation rate and the reasons of discontinuation among women who used or are current users of Long Acting Reversible Contraceptives, LARCs; implants, copper-IUD and levonorgestrel-releasing intrauterine system) and to compare with women who used or are current users of combined oral contraceptives (COCs), transdermal patch, vaginal ring, once-a-month or three-a-month injectables. All the medical records of women attended at the outpatient clinic of Familiy Planning of the University of Campinas (UNICAMP) who are current users or who used any contraceptive method between January 2, 1980 and December 30, 2010 will be review. Due to the fact that it is a pilot study we did not estimate the sample size; however, we estimated to review 46,000 files of women. The statistical analysis include life-table analysis according to Kaplan-Meier to gross rates of continuation and discontinuation according to each reason. After, we will analyze Cox proportional-hazard model to estimate the risk of accidental pregnancy for each method. The final analysis of the multivariate models will include adjustment for confounders and other variables which eventually could have any influence. The data of women with lost-to-follow-up will be censored at the last visit. For users of DMPA who did not return for a new injection we will consider 90 days after the last injection. The cases who used once-a-month injectables we will consider 30 days since the last injection. The statistical significance will be established on (alpha) of 0.05. The softwares SPSS v. 20.0 and Stata v. 7.0 will be use for analysis. (AU)